Evidence map›Paper›PMID 30026332›Full record

ArticleCancer research2018

Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs.

Monika Vishnoi, Debasish Boral, Haowen Liu, Marc L Sprouse, Wei Yin, Debalina Goswami-Sewell, Michael T Tetzlaff, Michael A Davies, Isabella C Glitza Oliva, Dario Marchetti

Abstract read
In one paragraph

Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. A review of deubiquitinases and thier roles in tumorigenesis and development.Frontiers in bioengineering and biotechnology · 2023
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Monika VishnoiBiomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas.
Debasish BoralBiomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas.ORCID 0000-0001-9505-9811
Haowen LiuBiomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas.
Marc L SprouseBiomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas.
Wei YinBiomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas.
Debalina Goswami-SewellBiomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas.
Michael T TetzlaffDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0977-0912
Isabella C Glitza OlivaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4530-7765
Dario MarchettiBiomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas. dmarchetti@houstonmethodist.org.

Funding

MOLECULAR DETERMINANTS OF BRAIN-METASTATIC MELANOMAR01CA086832 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MARCHETTI, DARIO · 2001 to 2010
$2.2M
Mechanisms of melanoma brain metastasis by CTCs isolated from patients' blood and CSFR01CA216991 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI MARCHETTI, DARIO · 2018 to 2024
$1.8M
Functional characterization of brain-colonizing breast cancer CTC subsetsR01CA193213 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI MARCHETTI, DARIO · 2015 to 2021
$1.8M
Heparanase Mechanisms in Brain-metastatic Breast CancerR01CA160335 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI MARCHETTI, DARIO · 2011 to 2015
$1.5M
NCI NIH HHS R01 CA086832NCI NIH HHS R01 CA160335NCI NIH HHS R01 CA193213NCI NIH HHS R01 CA216991
6 · The paper itself

Abstract

Systemic metastasis is the major cause of death from melanoma, the most lethal form of skin cancer. Although most patients with melanoma exhibit a substantial gap between onset of primary and metastatic tumors, signaling mechanisms implicated in the period of metastatic latency remain unclear. We hypothesized that melanoma circulating tumor cells (CTC) home to and reside in the bone marrow during the asymptomatic phase of disease progression. Using a strategy to deplete normal cell lineages (Lin

Indexed as

AnimalsBone MarrowBone Marrow CellsCell Line, TumorCell SurvivalDisease ProgressionDNA, MitochondrialGene Expression ProfilingHumansImmunophenotypingInflammationLeukocytes, MononuclearMelanomaMiceMice, Inbred NODNeoplasm MetastasisDNA, MitochondrialUbiquitin-Specific Peptidase 7USP7 protein, human

Identifiers

PMID30026332
PMCPMC6139068

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.